A detailed history of State Street Corp transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 2,049,542 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,049,542
Previous 1,856,221 10.41%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
N/A
193,321 Added 10.41%
2,049,542 $0
Q2 2024

Aug 14, 2024

BUY
N/A
251,671 Added 15.68%
1,856,221 $0
Q1 2024

May 15, 2024

BUY
N/A
1,027,570 Added 178.09%
1,604,550 $0
Q4 2023

Feb 14, 2024

BUY
N/A
40,820 Added 7.61%
576,980 $0
Q3 2023

Nov 14, 2023

BUY
N/A
97,609 Added 22.26%
536,160 $0
Q2 2023

Aug 14, 2023

BUY
N/A
309,360 Added 239.46%
438,551 $0
Q1 2023

May 15, 2023

BUY
N/A
43,300 Added 50.41%
129,191 $0
Q4 2022

Feb 14, 2023

BUY
$0.0 - $6.07 $0 - $111,081
18,300 Added 27.07%
85,891 $0
Q2 2022

Aug 15, 2022

SELL
$2.9 - $4.44 $802,148 - $1.23 Million
-276,603 Reduced 80.36%
67,591 $287,000
Q1 2022

May 16, 2022

BUY
$3.51 - $6.74 $70,835 - $136,019
20,181 Added 6.23%
344,194 $1.21 Million
Q4 2021

Feb 14, 2022

BUY
$6.03 - $11.67 $114,232 - $221,076
18,944 Added 6.21%
324,013 $2.16 Million
Q3 2021

Nov 15, 2021

BUY
$9.98 - $35.22 $805,885 - $2.84 Million
80,750 Added 36.0%
305,069 $3.05 Million
Q2 2021

Aug 16, 2021

BUY
$24.71 - $44.28 $794,550 - $1.42 Million
32,155 Added 16.73%
224,319 $6.93 Million
Q1 2021

May 17, 2021

BUY
$37.62 - $60.41 $7.23 Million - $11.6 Million
192,164 New
192,164 $8.38 Million

Others Institutions Holding SBTX

About Silverback Therapeutics, Inc.


  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.